IBT_B: Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push

About this update from Infant Bacterial Therapeutics Ab Class B

IBT completed its pivotal Phase 3 trial for IBP-9414, showing a significant reduction in all-cause mortality but missing primary endpoints. Financials reflect continued R&D investment, with strong cash reserves supporting regulatory and commercial plans. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B